ClinicalTrials.gg
CompletedNCT01105936Updated Jun 21, 2017Results posted

Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)

A Phase 4 interventional study of Paracetamol and Placebo in Osteoarthritis, Knee, sponsored by GlaxoSmithKline. Completed at 1 site in Spain. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2017-06-21.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing acetaminophen in Osteoarthritis, Knee — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis, Knee.

Enrollment
10th of 11
31 · median 300
Started
2010
the only one that year
Phase 4
Only one
of the 11
Registered
7th of 11
by date
Lead sponsor
1 of 11
GlaxoSmithKline

Among the 11 studies testing acetaminophen in Osteoarthritis, Knee, this one is the 10th largest by enrollment, is the only one that started in 2010, is the only one in phase 4, and was the 7th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

None of the 11 studies testing acetaminophen in Osteoarthritis, Knee is open now. The open studies under Osteoarthritis, Knee, anywhere →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing acetaminophen in Osteoarthritis, Knee as a file.
02

Study summary

Blood-Oxygen-Level-Dependent (BOLD) responses to painful mechanical stimulation of the OA knee following treatment with four consecutive doses (at 8 hour intervals) on giving sustained released paracetamol treatment or placebo will be compared. The fMRI and pain assessments will occur approximately 2-5 hours after taking the final dose.

Read the detailed description

The objective of this study is to investigate if functional magnetic response imaging (fMRI) can detect the effects of a known pain medicine at over-the-counter doses in people with osteoarthritis (OA) of the knee. The fMRI is a harmless and painless technique that is used in the current study to collect images of brain activity to see if is changed when feeling pain. In this study, BOLD response to mechanical stimulation via pressure stimuli applied to the tibio-femoral joint and patello-femoral in participants with knee OA following four treatment doses of any of three treatment will be compared.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • osteoarthritis
  • pain
  • paracetamol
  • Blood-Oxygen-Level-Dependent functional magnetic resonance imaging
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of osteoarthritis of at least one knee for 3 months
  • Male or female at least 45 years of age
  • Score a minimum of 4 out of 10 on the numerical pain rating and a maximum of 8 at screening

Exclusion criteria

Exclusion Criteria:

  • If female, is pregnant, lactating, or breast feeding
  • Has secondary cause of knee arthritis
  • Lower extremity surgery in the last 6 months
  • Prior injury in the last twelve months to the index knee
  • Used any analgesics (NSAIDs, COX2 inhibitor, etc) within 5 half lives of study start
  • Recently used oral or injected
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Paracetamol caplets

    Two 665 mg sustained release paracetamol caplets administered orally with water.

    Drug: Paracetamol

  • Placebo comparator
    Placebo caplets

    Two placebo caplets administered orally with water.

    Drug: Placebo

Interventions

  • 665 mg sustained release paracetamol caplets

  • DrugPlacebo

    Placebo caplets

06

What researchers measure

Primary outcomes

  1. Blood Oxygen Level-Dependent (BOLD) Response in the Tibio-femoral Joint of Knee Osteoarthritis (OA): [BOLD (T-f)]

    BOLD response to painful pressure stimuli was evaluated using fMRI. Voxel-wise BOLD scores were reported on a Z-scale (Gaussian,mean=0,SD=1); range -3 (worst score, lowest connectivity) to +3 (best score, highest connectivity). The software derived scores compared the intensity reading in the region to a template, specifically the Montreal Neurological Institute (MNI) Echo-Planar Image (EPI) template. The template provides, for each region, expected (mean/median) intensity for that region, along with expected variation. The BOLD score on the Z-scale represents how far the actual measured intensity is from the expected in the template. A score of 0 would correspond to the mean/median, a score of 1.65 would represent the 90-percentile, -1.65 the 10-percentile, and so on, according to a standard normal distribution.

    Time frame: Baseline to 2-5 hours post last dose administration

Secondary outcomes

  1. BOLD Response in the Patello-femoral Joint of Knee Osteoarthritis: [BOLD (P-f)]

    BOLD response to painful pressure stimuli was evaluated using fMRI. Voxel-wise BOLD scores were reported on a Z-scale (Gaussian,mean=0,SD=1); range -3 (worst score, lowest connectivity) to +3 (best score, highest connectivity). The software derived scores compared the intensity reading in the region to a template, specifically the Montreal Neurological Institute (MNI) Echo-Planar Image (EPI) template. The template provides, for each region, expected (mean/median) intensity for that region, along with expected variation. The BOLD score on the Z-scale represents how far the actual measured intensity is from the expected in the template. A score of 0 would correspond to the mean/median, a score of 1.65 would represent the 90-percentile, -1.65 the 10-percentile, and so on, according to a standard normal distribution

    Time frame: Baseline to 2-5 hours post last dose administration

  2. Subjective Numerical Rating Scale (NRS) Response for Treatment Effect on OA Knee Before Stimulation: [NRS (TRT)]

    Subjective NRS response for each participant was calculated as difference of pre-treatment NRS pain assessment before stimulus and post-treatment NRS pain assessment before stimulus. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

    Time frame: Baseline and post-dose before stimulus

  3. Subjective NRS Response for Treatment Effect on Tibio-femoral Stimulation Prior the fMRI Scan: [NRS (T-f Pre-scan)]

    Subjective NRS response was calculated for each participant as difference of pre-treatment pain assessment after stimulus and post-treatment pre-scan pain assessment after stimulus on tibio-femoral joint. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

    Time frame: Baseline and post-dose pre-scan after stimulus

  4. Subjective NRS Response for Treatment Effect on Patello-femoral Stimulation Prior the fMRI Scan: [NRS (P-f Pre-scan)]

    Subjective NRS response was calculated for each participant as difference of pre-treatment pain assessment after stimulus and post-treatment pre-scan pain assessment after stimulus on patello-femoral. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

    Time frame: Baseline and post-dose pre-scan after stimulus

  5. Subjective NRS Response for Treatment Effect on Tibio-femoral Stimulation After the fMRI Scan: [NRS (T-f Post-scan)]

    Subjective NRS response for treatment effect on tibio-femoral stimulus after the fMRI scan was calculated for each participant as difference of pre-treatment pain assessment after stimulus and post-treatment post-scan pain assessment after stimulus on tibio-femoral. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

    Time frame: Baseline and post-dose post-scan after stimulus

  6. Subjective NRS Response for Treatment Effect on Patello-femoral Stimulation After the fMRI Scan: [NRS (P-f Post-scan)]

    Subjective NRS response for each participant for treatment effect on tibio-femoral stimulus after the fMRI scan was calculated as difference of pre-treatment pain assessment after stimulus and post-treatment post-scan pain assessment after stimulus on patello-femoral. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

    Time frame: Baseline and post-dose post-scan after stimulus

07

Results

Posted Mar 24, 2015

Participant flow

Study was conducted at a single centre in Spain.

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started8878
Completed8877
Not completed0001
Withdrew: Adverse event0001
Wash-out Period 1
Participant flow — Wash-out Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started8877
Completed8877
Not completed0000
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started8877
Completed7877
Not completed1000
Withdrew: Adverse event1000
Wash-out Period 2
Participant flow — Wash-out Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started7877
Completed7877
Not completed0000
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started7877
Completed7677
Not completed0200
Withdrew: Protocol violation0200

Outcome measures

PrimaryBlood Oxygen Level-Dependent (BOLD) Response in the Tibio-femoral Joint of Knee Osteoarthritis (OA): [BOLD (T-f)]

BOLD response to painful pressure stimuli was evaluated using fMRI. Voxel-wise BOLD scores were reported on a Z-scale (Gaussian,mean=0,SD=1); range -3 (worst score, lowest connectivity) to +3 (best score, highest connectivity). The software derived scores compared the intensity reading in the region to a template, specifically the Montreal Neurological Institute (MNI) Echo-Planar Image (EPI) template. The template provides, for each region, expected (mean/median) intensity for that region, along with expected variation. The BOLD score on the Z-scale represents how far the actual measured intensity is from the expected in the template. A score of 0 would correspond to the mean/median, a score of 1.65 would represent the 90-percentile, -1.65 the 10-percentile, and so on, according to a standard normal distribution.

Time frame:
Baseline to 2-5 hours post last dose administration
Reported as:
Mean · Z-score
Blood Oxygen Level-Dependent (BOLD) Response in the Tibio-femoral Joint of Knee Osteoarthritis (OA): [BOLD (T-f)]
Z-scoreParacetamol 665 mgPlaceboNo Treatment
Blood Oxygen Level-Dependent (BOLD) Response in the Tibio-femoral Joint of Knee Osteoarthritis (OA): [BOLD (T-f)]NA ± NANA ± NANA ± NA
SecondaryBOLD Response in the Patello-femoral Joint of Knee Osteoarthritis: [BOLD (P-f)]

BOLD response to painful pressure stimuli was evaluated using fMRI. Voxel-wise BOLD scores were reported on a Z-scale (Gaussian,mean=0,SD=1); range -3 (worst score, lowest connectivity) to +3 (best score, highest connectivity). The software derived scores compared the intensity reading in the region to a template, specifically the Montreal Neurological Institute (MNI) Echo-Planar Image (EPI) template. The template provides, for each region, expected (mean/median) intensity for that region, along with expected variation. The BOLD score on the Z-scale represents how far the actual measured intensity is from the expected in the template. A score of 0 would correspond to the mean/median, a score of 1.65 would represent the 90-percentile, -1.65 the 10-percentile, and so on, according to a standard normal distribution

Time frame:
Baseline to 2-5 hours post last dose administration
Reported as:
Mean · Z-score
BOLD Response in the Patello-femoral Joint of Knee Osteoarthritis: [BOLD (P-f)]
Z-scoreParacetamol 665 mgPlaceboNo Treatment
BOLD - Sensory Cortex (a)0.16 ± 0.36NA ± NA0.48 ± 0.48
BOLD - Supramarginal Gyrus0.46 ± 0.48NA ± NA0.76 ± 0.49
BOLD - Thalamus0.48 ± 1.34-0.68 ± 1.74NA ± NA
BOLD - Subgenu PrefrontalNA ± NA-0.27 ± 0.410.19 ± 0.37
BOLD - Frontal CortexNA ± NA-0.04 ± 0.310.26 ± 0.42
BOLD - InsulaNA ± NA0.12 ± 0.510.62 ± 0.62
BOLD - Sensory Cortex (b)NA ± NA-0.11 ± 0.600.44 ± 0.48
SecondarySubjective Numerical Rating Scale (NRS) Response for Treatment Effect on OA Knee Before Stimulation: [NRS (TRT)]

Subjective NRS response for each participant was calculated as difference of pre-treatment NRS pain assessment before stimulus and post-treatment NRS pain assessment before stimulus. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

Time frame:
Baseline and post-dose before stimulus
Reported as:
Mean · Score on a Scale
Subjective Numerical Rating Scale (NRS) Response for Treatment Effect on OA Knee Before Stimulation: [NRS (TRT)]
Score on a ScaleParacetamol 665 Milligram (mg)PlaceboNo Treatment
Subjective Numerical Rating Scale (NRS) Response for Treatment Effect on OA Knee Before Stimulation: [NRS (TRT)]0.95 ± 1.67-0.52 ± 1.530.48 ± 1.83
SecondarySubjective NRS Response for Treatment Effect on Tibio-femoral Stimulation Prior the fMRI Scan: [NRS (T-f Pre-scan)]

Subjective NRS response was calculated for each participant as difference of pre-treatment pain assessment after stimulus and post-treatment pre-scan pain assessment after stimulus on tibio-femoral joint. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

Time frame:
Baseline and post-dose pre-scan after stimulus
Reported as:
Mean · Score on a Scale
Subjective NRS Response for Treatment Effect on Tibio-femoral Stimulation Prior the fMRI Scan: [NRS (T-f Pre-scan)]
Score on a ScaleParacetamol 665 mgPlaceboNo Treatment
Subjective NRS Response for Treatment Effect on Tibio-femoral Stimulation Prior the fMRI Scan: [NRS (T-f Pre-scan)]0.55 ± 0.890.17 ± 1.070.00 ± 0.74
SecondarySubjective NRS Response for Treatment Effect on Patello-femoral Stimulation Prior the fMRI Scan: [NRS (P-f Pre-scan)]

Subjective NRS response was calculated for each participant as difference of pre-treatment pain assessment after stimulus and post-treatment pre-scan pain assessment after stimulus on patello-femoral. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

Time frame:
Baseline and post-dose pre-scan after stimulus
Reported as:
Mean · Score on a Scale
Subjective NRS Response for Treatment Effect on Patello-femoral Stimulation Prior the fMRI Scan: [NRS (P-f Pre-scan)]
Score on a ScaleParacetamol 665 mgPlaceboNo Treatment
Subjective NRS Response for Treatment Effect on Patello-femoral Stimulation Prior the fMRI Scan: [NRS (P-f Pre-scan)]0.60 ± 1.230.43 ± 0.950.00 ± 0.91
SecondarySubjective NRS Response for Treatment Effect on Tibio-femoral Stimulation After the fMRI Scan: [NRS (T-f Post-scan)]

Subjective NRS response for treatment effect on tibio-femoral stimulus after the fMRI scan was calculated for each participant as difference of pre-treatment pain assessment after stimulus and post-treatment post-scan pain assessment after stimulus on tibio-femoral. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

Time frame:
Baseline and post-dose post-scan after stimulus
Reported as:
Mean · Score on a Scale
Subjective NRS Response for Treatment Effect on Tibio-femoral Stimulation After the fMRI Scan: [NRS (T-f Post-scan)]
Score on a ScaleParacetamol 665 mgPlaceboNo Treatment
Subjective NRS Response for Treatment Effect on Tibio-femoral Stimulation After the fMRI Scan: [NRS (T-f Post-scan)]0.15 ± 1.180.09 ± 1.38-0.13 ± 1.10
SecondarySubjective NRS Response for Treatment Effect on Patello-femoral Stimulation After the fMRI Scan: [NRS (P-f Post-scan)]

Subjective NRS response for each participant for treatment effect on tibio-femoral stimulus after the fMRI scan was calculated as difference of pre-treatment pain assessment after stimulus and post-treatment post-scan pain assessment after stimulus on patello-femoral. NRS responses was based on an 11 scale rating (0-10), with 0 corresponding to "No Pain" and 10 corresponding to "Extreme Pain or Pain as bad as you can imagine".

Time frame:
Baseline and post-dose post-scan after stimulus
Reported as:
Mean · Score on a Scale
Subjective NRS Response for Treatment Effect on Patello-femoral Stimulation After the fMRI Scan: [NRS (P-f Post-scan)]
Score on a ScaleParacetamol 665 mgPlaceboNo Treatment
Subjective NRS Response for Treatment Effect on Patello-femoral Stimulation After the fMRI Scan: [NRS (P-f Post-scan)]0.30 ± 1.66-0.48 ± 1.62-0.39 ± 1.92

Adverse events

Collected over Adverse Events were collected from the time of start of the investigational product, and until 5 days following last administration of the investigational product.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paracetamol 665 mg—0/29 (0%)3/29 (10.3%)
Placebo—0/28 (0%)3/28 (10.7%)
No Treatment—0/30 (0%)2/30 (6.7%)
Most frequent other events
Most frequent other events
EventParacetamol 665 mgPlaceboNo Treatment
AnxietyPsychiatric disorders1/291/280/30
DiarrhoeaGastrointestinal disorders0/291/280/30
HeadacheNervous system disorders0/291/280/30
Dental cariesGastrointestinal disorders1/290/280/30
Bone PainMusculoskeletal and connective tissue disorders1/290/280/30
ClaustrophobiaPsychiatric disorders0/290/281/30
LacerationInjury, poisoning and procedural complications0/290/281/30

Baseline characteristics

Age, Customized
Age, Customized(Years)Total Participants for Baseline Measurement
Years68.5 ± 7.97
Sex: Female, Male
Sex: Female, Male(Participants)Total Participants for Baseline Measurement
Female26
Male4
08

Study locations

1 site
  • Hospital Del Mar
    Barcelona, CP: 08003, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Apr 19, 2010
Start
Sep 1, 2010
Primary completionActual
Aug 1, 2011
CompletionActual
Aug 1, 2011
Results first posted
Mar 24, 2015
Last update
Jun 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01105936
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 19, 2010
Start date
Sep 1, 2010
Primary completion
Aug 1, 2011
Completion
Aug 1, 2011
Results posted
Mar 24, 2015
Last update
Jun 21, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion